drugset / Trial / NCT06132867
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
RandomizedCrossoverOpen-labelBasic science
Summary
The main aim of this study is to compare the amount of brigatinib in the blood of healthy adults after they have swallowed one dose either as a solution or as a tablet.
Timeline
- Start
- 2023-12-20
- Primary completion
- 2024-02-17
- Completion
- 2024-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brigatinib | Small molecule | 90 mg | Oral |
Indications
No indication recorded.